Able Star

AbleStar is a clinical-stage biopharmaceutical company and a subsidiary of Harbour BioMed, specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company leverages its proprietary AbleStar platform to design "smart" antibodies that are selectively activated within the tumor microenvironment, which aims to improve the therapeutic index by reducing systemic toxicity. Its lead asset, HBM9033 (AS-01), is a Claudin 18.2-targeting ADC that is currently being evaluated in Phase 1 clinical trials and was recently licensed to Pfizer for global development. AbleStar's pipeline also includes several other ADC candidates and multi-specific antibodies targeting solid tumors. The company is headquartered in Suzhou, China, and operates as the dedicated ADC arm of Harbour BioMed.